Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients

Kazuo Notsumata; Yoshimoto Nomura; Akihiro Tanaka; Teruyuki Ueda; Taku Sanada; Hiroyuki Watanabe; Daishu Toya

doi:10.1111/hepr.13451

Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients

Hepatol Res. 2020 Mar;50(3):402-404. doi: 10.1111/hepr.13451.

Authors

Kazuo Notsumata¹, Yoshimoto Nomura¹, Akihiro Tanaka¹, Teruyuki Ueda¹, Taku Sanada¹, Hiroyuki Watanabe¹, Daishu Toya¹

Affiliation

¹ Department of General Internal Medicine, Fukui-ken Saiseikai Hospital, 7-1 WadanakachoFunahashi, Fukui-shi, Fukui-ken, Japan.

PMID: 31692220
DOI: 10.1111/hepr.13451

No abstract available

Keywords: chronic hepatitis B; entecavir; fibroblast growth factor 23; phosphorus metabolism; renal tubular dysfunction; tenofovir alafenamide; urinary liver-type fatty acid-binding protein.

Publication types

Letter